Preclinical models have shown that inhibition of kinases in mitogenic and angiogenic signaling pathways can have antitumoral effects. Starting with a brief synopsis of a malignancy that responds well to kinase inhibition (chronic myeloid leukemia) compared with one with less durable responses as yet (melanoma), this Review highlights challenges that must be overcome in order to successfully translate small-molecule therapies to thyroid cancer in the future.
- Matti L. Gild
- Martyn Bullock
- Roderick Clifton-Bligh